Ground Swell Capital LLC Grows Stock Holdings in VolitionRx Limited (NYSE:VNRX)

Ground Swell Capital LLC lifted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period.

VolitionRx Stock Up 9.9 %

VNRX opened at $0.60 on Monday. The company has a market cap of $55.68 million, a P/E ratio of -1.51 and a beta of 1.10. The firm’s 50-day moving average price is $0.68 and its 200-day moving average price is $0.69. VolitionRx Limited has a 52-week low of $0.43 and a 52-week high of $1.23.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.34 million. On average, research analysts anticipate that VolitionRx Limited will post -0.31 EPS for the current fiscal year.

Insider Activity at VolitionRx

In other news, Director Guy Archibald Innes purchased 150,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was bought at an average price of $0.67 per share, with a total value of $100,500.00. Following the transaction, the director now owns 406,683 shares in the company, valued at $272,477.61. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on VNRX shares. Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, August 16th. StockNews.com assumed coverage on shares of VolitionRx in a research note on Monday. They set a “sell” rating for the company.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.